The struggling genetic-testing 23andMe is looking for a buyer for the virtual-care business it acquired in 2021, Business ...

Genetic testing firm 23andMe is reportedly considering the sale of its telehealth division, Lemonaid Health, according to ...

Shares in 23andMe are currently trading at around $3.40, giving it a valuation of just under $82 million. The company went ...

Me still merchandises its ancestry, health analysis, and the Total Health annual package on a scale from $99 to $999 annually. Lemonaid entered the hot GLP-1 prescribing and support business in 2024, ...

The struggling health company bought the virtual-care startup Lemonaid in 2021 for $400 million. 23andMe's stock plummeted after a 2023 data breach exposed millions of customer accounts.